medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2018, Number 6

<< Back Next >>

Rev Mex Oftalmol 2018; 92 (6)

Macular edema in Vogt-Koyanagi-Harada syndrome treated with antiangiogenic therapy. Case report

Flores-Peraza MA, González-Camarena PI, Martínez-del Villar G, Rios-Prado R, Díaz-del-Castillo-Martín EA

Language: Spanish
References: 12
Page: 305-309
PDF size: 802.90 Kb.


ABSTRACT

50% of patients with syndrome Vogt-Koyanagi-Harada presents ocular complications, 5-10% have neovascular membrane and macular edema. We present a 39-year-old woman with macular edema secondary to syndrome Vogt-Koyanagi-Harada, treated with antiangiogenic intravitreal injections and its evolution was objectively followed with optical coherence tomography. Discussion: Antiangiogenic intravitreal injections are an alternative for the treatment of macular edema secondary to inflammatory eye diseases compared to conventional therapy with sub-Tenon steroids and intravitreal injections.


REFERENCES

  1. Riveros Frutos A, Romera Romero P, Holgado Pérez S, et al. Enfermedad de Vogt-Koyanagi-Harada. Semin Fund Esp Reuma-tol. 2012;13:142-6.

  2. Tsai JH, Evans M, Rao NA. Comparative study of two sets of criteria for the diagnosis of Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2006;141:778-9.

  3. Tranos PG, Wickremasinghe SS, Stangos NT, et al. Macularedema. Surv Ophthalmol. 2004;49:470-90.

  4. Davis MD, Fisher MR. Diabetic macular oedema. Am J Ophthal-mol. 2003;110:77-82.

  5. Kowanetz M, Ferrara N. Vascular endothelial growth factor sig-naling pathways: Therapeutic perspective. Clin Cancer Res. 2006;12:5018-22.

  6. Madanlou HD, Gharraee Z, Hasan J, et al. Ontogeny of VEGF, IGF-I and GH in neonatal rat serum, vitreous fluid, and retina from birth to weaning. Invest Ophthalmol Vis Sci. 2006;47:738-44.

  7. Kvanta A. Ocular angiogenesis: The role of growth factors. Acta Ophthalmol Scand. 2006;84:282-8.

  8. Yoo MH, Hyun HJ, Kob JY, et al. Riluzole inhibits VEGF-inducedendothelial cell proliferation in vitro and hyoeroxia-inducedabnormal vessel formation in vivo. Invest Ophthalmol Vis Sci. 2005;46:4780-7.

  9. Hutcheson KA. Retinopathy of prematurity. Curr Opin Ophthal-mol. 2003;14:286-90.

  10. Manzano RP, Peyman GA, Khan P, et al. Testing intravitreal toxi-city of bevacizumab (Avastin). Retina. 2006;26:257-61.

  11. Dorrell M, Uusitalo-Jarvinen H, Aguilar E, et al. Ocular neovas-cularization: Basic mechanisms and therapeutic advances. SurvOphthalmol. 2007;52:S3-19.

  12. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treat-ment of neovascular age-related macular degeneration: A phasei/ii multicenter, controlled, multidose study. Ophthalmology.2006;113:642-4.




2020     |     www.medigraphic.com